In this issue the NOTION TRIAL looks at the cost-effectiveness of TAVI in patients at lower surgical risk; the final results of the REDUCE trial examining the optimal duration of DAPT in ACS patients treated with DES; a look at the impact of FFR in guiding CABG – the GRAFFITI trial; BIOFLOW-IV, studying the Orsiro sirolimus-eluting stent; and a study of multivessel PCIs in patients with acute myocardial infarction (AMI) and severe renal dysfunction.
Coisne A, Pontana F, Tchétché D, Richardson M, Longère B, Vahdat O, Berthoumieu P, Van Belle E, Rousse N, Lancellotti P, Montaigne D, Dumonteil N, Modine T
Toth GG, De Bruyne B, Kala P, Ribichini F, Casselman F, Ramos R, Piróth Z, Fournier S, Piccoli A, van Mieghem C, Penicka M, Mates M, Nemec P, Van Praet F, Stockman B, Degriek I, Barbato E